Satsuma Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Satsuma Pharmaceuticals

11/03/2023 24:51

* Satsuma Pharmaceuticals Inc  STSA.OQ   STSA.O  is expected
to show no change in quarterly revenue when it reports 
results on March 13 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Satsuma
Pharmaceuticals
Inc is for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Satsuma
Pharmaceuticals Inc is $2.5​, above​ its last closing price
of $0.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.54       -0.54      -0.48     Beat    11.6
 Jun. 30 2022  -0.50       -0.49      -0.52     Missed  -6.1
 Mar. 31 2022  -0.48       -0.49      -0.49     Met     0.7​
 Dec. 31 2021              -0.48      -0.49     Missed  -1
 ​​Sep.                    -0.51      -0.42     Beat    17.6
 30 2021                                                
 Jun. 30 2021  -0.41       -0.41      -0.38     Beat    8.1​
 Mar. 31 2021  -0.41       -0.42      -0.48     Missed  -15.2
 Dec. 31 2020  -0.65       -0.53      -0.72     Missed  -36.2
 This summary was machine generated March 11 at 00:51 GMT.  All
figures in US dollars  unless otherwise stated